Amgen (AMGN) Offering Possible 50.15% Return Over the Next 14 Calendar Days

Amgen's most recent trend suggests a bullish bias. One trading opportunity on Amgen is a Bull Put Spread using a strike $177.50 short put and a strike $172.50 long put offers a potential 50.15% return on risk over the next 14 calendar days. Maximum profit would be generated if the Bull Put Spread were to expire worthless, which would occur if the stock were above $177.50 by expiration. The full premium credit of $1.67 would be kept by the premium seller. The risk of $3.33 would be incurred if the stock dropped below the $172.50 long put strike price.

The 5-day moving average is moving up which suggests that the short-term momentum for Amgen is bullish and the probability of a rise in share price is higher if the stock starts trending.

The 20-day moving average is moving up which suggests that the medium-term momentum for Amgen is bullish.

The RSI indicator is at 72.65 level which suggests that the stock is neither overbought nor oversold at this time.

To learn how to execute such a strategy while accounting for risk and reward in the context of smart portfolio management, and see how to trade live with a successful professional trader, view more here


LATEST NEWS for Amgen

Why Amgen Expects EPS to Rise in 2018
Wed, 30 May 2018 21:30:02 +0000
Amgen (AMGN) has projected its non-GAAP EPS for 2018 at $12.60–$13.70. That assumes a non-GAAP tax rate guidance of 13.5%–14.5%, which is lower than the previously projected range of 14%–15%. That can be attributed to the realization of certain favorable one-time events associated with the Tax Cuts and Jobs Act passed in 2017. It also expects to witness capital expenditures of $750 million in 2018.

Why Amgen Revised Its Revenue Guidance for 2018
Wed, 30 May 2018 20:00:02 +0000
In its first-quarter conference call, Amgen (AMGN) revised its revenue guidance from $21.8 billion–$22.8 billion to $21.9 billion–$22.8 billion. Amgen saw strong demand trends in the first quarter for Parsabiv, its other calcimimetic drug that has been launched in the United States as well as international markets. Its peers Biogen (BIIB), Celgene (CELG), and Gilead Sciences (GILD) are expected to report revenues of $12.9 billion, $14.9 billion, and $20.8 billion, respectively, in 2018.

Amgen Foundation And Harvard Team Up To Offer Free Online Science Education Platform
Wed, 30 May 2018 20:00:00 +0000
THOUSAND OAKS, Calif. and CAMBRIDGE, Mass., May 30, 2018 /PRNewswire/ — The Amgen Foundation and Harvard University today announced plans to launch a free online science education platform uniquely designed to level the playing field for aspiring scientists. The LabXchange platform, which will launch with a focus in biology, will offer digital instruction and virtual lab experiences to high school and college students, enabling them to gain meaningful exposure to the scientific process. “There are many millions of students who, as a result of economic or geographic limitations, simply do not have access to one of the most central aspects of being a scientist, which is working in a laboratory,” said Professor Robert Lue, principal investigator of LabXchange and professor of the Practice of Molecular and Cellular Biology at Harvard.

Analyst Recommendations for Amgen and Its Peers in May
Wed, 30 May 2018 18:27:49 +0000
In the first quarter, Amgen (AMGN) reported total revenues of $5.6 billion, which is a YoY (year-over-year) rise of 2%. It also reported total product sales of $5.3 billion, a YoY rise of 3% and a sequential decline of 4%. Sales were boosted by a double-digit rise in unit sales for all of Amgen’s recently launched products, including Xgeva, Prolia, Repatha, and Kyprolis.

Biotech ETFs Are the Best Way to Play the Recovering Sector
Wed, 30 May 2018 15:43:14 +0000
The summer of 2015 marked the end of the glory years in the biotechnology sector. The biotech valuation correction that lasted over two years may be coming to an end. Some well-known, large-cap names — such as AbbVie Inc (NYSE:ABBV) and Pfizer Inc. (NYSE:PFE) — are currently trading at forward P/E multiples in the 10+ range.

Be Sociable, Share!

Related Posts

 

MarketTamer is not an investment advisor and is not registered with the U.S. Securities and Exchange Commission or the Financial Industry Regulatory Authority. Further, owners, employees, agents or representatives of MarketTamer are not acting as investment advisors and might not be registered with the U.S. Securities and Exchange Commission or the Financial Industry Regulatory.


This company makes no representations or warranties concerning the products, practices or procedures of any company or entity mentioned or recommended in this email, and makes no representations or warranties concerning said company or entity’s compliance with applicable laws and regulations, including, but not limited to, regulations promulgated by the SEC or the CFTC. The sender of this email may receive a portion of the proceeds from the sale of any products or services offered by a company or entity mentioned or recommended in this email. The recipient of this email assumes responsibility for conducting its own due diligence on the aforementioned company or entity and assumes full responsibility, and releases the sender from liability, for any purchase or order made from any company or entity mentioned or recommended in this email.


The content on any of MarketTamer websites, products or communication is for educational purposes only. Nothing in its products, services, or communications shall be construed as a solicitation and/or recommendation to buy or sell a security. Trading stocks, options and other securities involves risk. The risk of loss in trading securities can be substantial. The risk involved with trading stocks, options and other securities is not suitable for all investors. Prior to buying or selling an option, an investor must evaluate his/her own personal financial situation and consider all relevant risk factors. See: Characteristics and Risks of Standardized Options. The www.MarketTamer.com educational training program and software services are provided to improve financial understanding.


The information presented in this site is not intended to be used as the sole basis of any investment decisions, nor should it be construed as advice designed to meet the investment needs of any particular investor. Nothing in our research constitutes legal, accounting or tax advice or individually tailored investment advice. Our research is prepared for general circulation and has been prepared without regard to the individual financial circumstances and objectives of persons who receive or obtain access to it. Our research is based on sources that we believe to be reliable. However, we do not make any representation or warranty, expressed or implied, as to the accuracy of our research, the completeness, or correctness or make any guarantee or other promise as to any results that may be obtained from using our research. To the maximum extent permitted by law, neither we, any of our affiliates, nor any other person, shall have any liability whatsoever to any person for any loss or expense, whether direct, indirect, consequential, incidental or otherwise, arising from or relating in any way to any use of or reliance on our research or the information contained therein. Some discussions contain forward looking statements which are based on current expectations and differences can be expected. All of our research, including the estimates, opinions and information contained therein, reflects our judgment as of the publication or other dissemination date of the research and is subject to change without notice. Further, we expressly disclaim any responsibility to update such research. Investing involves substantial risk. Past performance is not a guarantee of future results, and a loss of original capital may occur. No one receiving or accessing our research should make any investment decision without first consulting his or her own personal financial advisor and conducting his or her own research and due diligence, including carefully reviewing any applicable prospectuses, press releases, reports and other public filings of the issuer of any securities being considered. None of the information presented should be construed as an offer to sell or buy any particular security. As always, use your best judgment when investing.